ESCRS - P089 - VISUAL OUTCOMES AFTER BILATERAL IMPLANTATION OF ACRYSOF™ IQ VIVITY™ EXTENDED VISION INTRAOCULAR LENS

VISUAL OUTCOMES AFTER BILATERAL IMPLANTATION OF ACRYSOF™ IQ VIVITY™ EXTENDED VISION INTRAOCULAR LENS

Published 2022 - 26th ESCRS Winter Meeting

Reference: P089 | Type: Abstracts | DOI: 10.82333/4kht-3660

Authors: Andreas Katsimpris* 1 , Konstantina Chronopoulou 1 , Alessandro Di Maggio 2 , Maria Alexaki 3 , George Kymionis 1

1Ophthalmology Department,General Hospital of Athens “Georgios Gennimatas”, Athens, Greece,Athens,Greece, 2Ophthalmology Department,University of Siena,Siena,Italy, 3Ophthalmology Department,Eye Day Clinic,Athens,Greece

Purpose

To assess the visual and refractive outcomes of the non-diffractive extended depth of focus (EDOF) AcrySof ® IQ Vivity™ (Alcon, Fort Worth, TX, USA) intraocular lens (IOL) after bilateral implantation in patients undergoing phacoemulsification surgery.

Setting

In this prospective non-comparative study, 20 patients willing to undergo bilateral implantation of  AcrySof ® IQ Vivity™ IOL from an experienced ophthalmic surgeon were recruited at a single center (Eye Day Clinic, Athens, Greece). 

Methods

Pre- and post-operative clinical assessment of the patients included slit lamp examination, assessment of corrected distance visual acuity (CDVA) at 6 m, uncorrected distance visual acuity (UDVA) at 6 m, uncorrected intermediate visual acuity (UIVA) at 66 cm, uncorrected near visual acuity (NDVA) at 33 cm and optical biometry. Moreover, the presence of visual disturbances and the contrast sensitivity (CS) thresholds of all patients were assessed.

Results

The mean ± standard deviation (SD) of monocular UDVA, UIVA and UNVA were 0.05 ± 0.08, 0.07 ± 0.09 and 0.23 ± 0.09 LogMAR, respectively. More specifically, 97.5%, 70% and 15% of eyes achieved UDVA, UIVA and UNVA of 20/25 or higher, while 6 patients in total reported mild glare, blurred vision, fluctuation in vision and/or depth perception difficulty. The mean ± SD of LogCS threshold was 1.68 ± 0.26.

Conclusion

Bilateral implantation of AcrySof ® IQ Vivity™ IOL could be a solution to patients seeking independence from optical aids. Further comparative studies are warranted to confirm our results.